Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia.
BMC Med Res Methodol. 2021 Jun 14;21(1):122. doi: 10.1186/s12874-021-01313-x.
Attrition is a major obstacle for lifestyle interventions sustained for the medium-to-long term and can have significant consequences on the internal validity of a trial. When the degree of attrition differs between active and control arms this is termed differential attrition and is an important consideration during initial stages of trial planning.
The primary research question of this study was: what is the differential attrition between treatment arms in lifestyle interventions for prevalent chronic diseases?
We performed a systematic review and meta-analysis of 23 studies involving a lifestyle intervention component in cohorts with chronic diseases. The search accessed three databases: Scopus, Medline Ovid and Web of Science. Attrition between treatment arms was analysed using a random-effects model and examined the relationship between the relative attrition and potential moderators, such as time to final follow-up, time to first follow-up, type of disease, type of control, type of intervention and length of treatment.
The pooled risk ratio was 1.00 (95% CI 0.97 - 1.03) and only one study fell outside this range. A univariable association was described between the pooled risk ration and length (years) to final follow-up, which did not remain in the multivariable model.
Ultimately, we found no evidence of differential attrition in medium-to-long term lifestyle intervention studies for chronic disease, increasing confidence in conducting such studies with minimal potential of attrition bias.
PROSPERO registration number CRD42018084495 .
在中-长期的生活方式干预中,人员流失是一个主要障碍,这可能对试验的内部有效性产生重大影响。当活跃组和对照组之间的人员流失程度存在差异时,这被称为差异流失,这是在试验规划的初始阶段需要考虑的一个重要因素。
本研究的主要研究问题是:在针对常见慢性病的生活方式干预中,治疗组之间的差异流失程度是多少?
我们对涉及慢性病队列的 23 项生活方式干预研究进行了系统评价和荟萃分析。检索了三个数据库:Scopus、Medline Ovid 和 Web of Science。使用随机效应模型分析治疗组之间的人员流失情况,并研究了相对流失与潜在调节因素之间的关系,如最终随访时间、首次随访时间、疾病类型、对照组类型、干预类型和治疗时间长度。
合并后的风险比为 1.00(95%置信区间 0.97-1.03),只有一项研究不在这个范围内。在单变量分析中,我们描述了合并后的风险比与最终随访时间(年)之间存在关联,但在多变量模型中这一关联并不存在。
最终,我们没有发现中-长期慢性病生活方式干预研究中存在差异流失的证据,这增加了对开展此类研究的信心,认为此类研究具有最小的流失偏倚风险。
PROSPERO 注册号 CRD42018084495。